

DESCRIPTION





Species Reactivity	Mouse/Rat
Specificity	Detects mouse CD31/PECAM-1 in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 10% cross-reactivity with recombinant human CD31 and recombinant porcine CD31 is observed. Detects mouse CD31 and rat CD31 in flow cytometry.
Source	Polyclonal Goat IgG
Purification	Antigen Affinity-purified
Immunogen	Mouse myeloma cell line NS0-derived recombinant mouse CD31/PECAM-1 Glu18-Lys590 Accession # Q08481
Endotoxin Level	<0.10 EU per 1 µg of the antibody by the LAL method.
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

APPLICATIONS


Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

	Recommended Concentration	Sample
Western Blot	0.5 µg/mL	See Below
Flow Cytometry	0.25 µg/10 ⁶ cells	See Below
Immunocytochemistry	5-15 µg/mL	See Below
Immunohistochemistry	5-15 µg/mL	See Below
CyTOF-ready	Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.	

DATA




Immunohistochemistry



CD31/PECAM-1 in Mouse Embryo. CD31/PECAM-1 was detected in immersion fixed frozen sections of mouse embryo (E13.5) using Goat Anti-Mouse/Rat CD31/PECAM-1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF3628) at 10 µg/mL overnight at 4 °C. Tissue was stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (yellow; Catalog # NL001) and counterstained with DAPI (blue). Specific staining was localized to developing endothelium. View our protocol for [Fluorescent IHC Staining of Frozen Tissue Sections](#).

Immunohistochemistry



CD31/PECAM-1 in Mouse Embryo. CD31/PECAM-1 was detected in immersion fixed frozen sections of mouse embryo (14 d.p.c.) using Goat Anti-Mouse/Rat CD31/PECAM-1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF3628) at 10 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Goat IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC004). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to developing guts. View our protocol for [IHC Staining with VisUCyte HRP Polymer Detection Reagents](#).

PREPARATION AND STORAGE

Reconstitution	Reconstitute at 0.2 mg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> • 12 months from date of receipt, -20 to -70 °C as supplied. • 1 month, 2 to 8 °C under sterile conditions after reconstitution. • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

PECAM-1 (Platelet-Endothelial Cell Adhesion Molecule-1), also known as CD31, is a 130 kDa type I transmembrane glycoprotein adhesion molecule in the immunoglobulin superfamily (1, 2). Expression is restricted to cells involved in circulation, especially endothelial cells, platelets, monocytes, neutrophils and lymphocyte subsets. PECAM-1 is concentrated at cell-cell junctions and is required for Transendothelial Migration (TEM) (1-3). The Extracellular Domain (ECD) of PECAM-1 has ten potential N-linked glycosylation sites and six C2-type Ig-like domains, the first of which is critical for adhesion and extravasation (3, 4). The cytoplasmic domain contains Immunoregulatory Tyrosine-based Inhibitory and Switch Motifs (ITIM, ITSM) that mediate both inhibition and activation via phosphotyrosine-mediated engagement of SH2-containing signaling molecules (1, 5). Metalloproteinase-mediated ectodomain shedding occurs during apoptosis (6) but increased serum PECAM-1 ectodomain in HIV and active multiple sclerosis occurs independent of apoptosis (7, 8). In humans, expression of six isoforms with exon deletions in the cytoplasmic domain is tissue- and stage-specific, but full-length PECAM-1 is predominant. A form lacking the ITSM predominates in mouse (9). Mouse PECAM-1 ECD shows 77%, 63%, 63%, 63%, and 61% amino acid (aa) identity with rat, human, canine, porcine, and bovine PECAM-1, respectively. PECAM-1 participates with other adhesion molecules in some functions, but is the critical molecule for TEM. Homotypic PECAM-1 adhesion in trans, combined with cycling of PECAM-1 to and from surface-connected endothelial cell vesicles, leads leukocytes across endothelial tight junctions (3, 10). Homotypic adhesion and signaling functions also strongly suppress mitochondria-dependent apoptosis (11). In platelets, PECAM-1 is necessary for limiting thrombus formation (12) and promoting integrin-mediated clot retraction and platelet spreading (13), but mechanisms for these phenomena are unclear. PECAM-1^{-/-} mice are deficient in chemokine-mediated chemotaxis (14).

References:

1. Ilan, N. and J.A. Madri (2003) *Curr. Opin. Cell Biol.* **15**:515.
2. Xie, Y. and W.A. Muller (1993) *Proc. Natl. Acad. Sci. USA* **90**:5569.
3. Liao, F. *et al.* (1997) *J. Exp. Med.* **185**:1349.
4. Nakada, M.T. *et al.* (2000) *J. Immunol.* **164**:452.
5. Chemnitz, J.M. *et al.* (2004) *J. Immunol.* **173**:945.
6. Ilan, N. *et al.* (2001) *FASEB J.* **15**:362.
7. Eugenin, E.A. *et al.* (2006) *J. Leukoc. Biol.* **79**:444.
8. Losy, J. *et al.* (1999) *J. Neuroimmunol.* **99**:169.
9. Wang, Y. *et al.* (2003) *Am. J. Physiol. Heart Circ. Physiol.* **284**:H1008.
10. Mamdouh, Z. *et al.* (2003) *Nature* **421**:748.
11. Gao, C. *et al.* (2003) *Blood* **102**:169.
12. Falati, S. *et al.* (2006) *Blood* **107**:535.
13. Wee, J.L. and D.E. Jackson (2005) *Blood* **106**:3816.
14. Wu, Y. *et al.* (2005) *J. Immunol.* **175**:3484.